Journal
KIDNEY INTERNATIONAL
Volume 80, Issue 3, Pages 237-239Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ki.2011.133
Keywords
-
Categories
Ask authors/readers for more resources
Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available